Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Merck to acquire respiratory drug maker, Verona Pharma for $10 billion: Rahway, New Jersey Thursday, July 10, 2025, 09:00 Hrs [IST] Merck, known as MSD outside of the United State ...

Merck, through a subsidiary, will acquire Verona Pharma for a total transaction value of approximately $10 billion.

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

Merck announced plans to acquire Verona Pharma for roughly $10 billion. 1 As part of the agreement between the two companies, Merck will add Verona’s COPD treatment Ohtuvayre to its cardio-pulmonary ...

The transaction will enhance Merck's cardio-pulmonary pipeline and portfolio with the addition of Ohtuvayre, an FDA-approved COPD treatment.

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Verona Pharma plc, a biopharmaceutical company ...

Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant's portfolio of chronic obstructive pulmonary disease treatments with Verona Pharma's ...